ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1998

Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies
Abstract Number: 1999

Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials
Abstract Number: 2000

Can Uric Acid Protect Joints? Lower Incidence of Large Joint Replacements Among Individuals with Higher SUA
Abstract Number: 2001

Characteristics of Gout Flares Over Time with Treat-to-Target Urate-Lowering Therapy Use
Abstract Number: 2002

Methods to Address Survival Bias and Competing Risks in Estimating the Causal Risks of Gout on Dementia Risk
Abstract Number: 2003

Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data
Abstract Number: 2004

Characteristics and Management of Gout Patients Under Rheumatologist Care from Low-Income and Middle-Income Asia-Pacific Countries: Data from the APLAR Gout Registry
Abstract Number: 2005

Elevated Serum Uric Acid as an Independent Risk Factor for Multiple Stent Placement in Non-Hypertensive, Non-Diabetic Patients with Coronary Artery Disease: A Retrospective Cohort Analysis
Abstract Number: 2006

Storytelling and Navigation to Improve Gout Follow-up: A Multicenter, Randomized Controlled Trial
Abstract Number: 2007

Machine Learning-Based Prediction of Gout Onset in Individuals with Asymptomatic Hyperuricemia Using a Common Data Model
Abstract Number: 2008

Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)
Abstract Number: 2009

Value of New PREVENT Calculator in Detecting Cardiovascular Disease in Patients with Gout
Abstract Number: 2010

Innate Transcriptional Response and Control of Expression of the Gout-Associated Colony Stimulating Factor-1 (CSF1) and CSF1 Receptor (CSF1R) Genes to Stimuli
Abstract Number: 2011

A Phase 1 placebo controlled, single (SAD) and multiple dose escalation (MAD) safety and pharmacokinetic (PK) study of a novel colchicine analogue ABP-745 in healthy volunteers (HV)
Abstract Number: 2012

A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].